• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

    1.350 -0.070 (-4.93%)
    Streaming Delayed Price Updated: 12:45 PM EST, Mar 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 79,187
    Open 1.430
    Bid (Size) 1.350 (300)
    Ask (Size) 1.360 (600)
    Prev. Close 1.420
    Today's Range 1.330 - 1.430
    52wk Range 1.110 - 7.190
    Shares Outstanding 736,213
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill

    Performance

    YTD
    -26.6%
    -26.6%
    1 Month
    -8.2%
    -8.2%
    3 Month
    -18.2%
    -18.2%
    6 Month
    -50.4%
    -50.4%
    1 Year
    -75.6%
    -75.6%

    More News

    Read More
    News headline image
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    $1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside
    Via AB Newswire
    News headline image
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire

    Frequently Asked Questions

    Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?
    Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.
    What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?
    Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?
    The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market
    What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?
    The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 1.350
    When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?
    The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 03/05/26 12:45 PM ET
    What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?
    The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 993.89K
    How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?
    Jasper Therapeutics, Inc. - Class A Common Stock has 994K shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.